

Spring Group Meeting

# San Francisco Specials

APRIL 30 - MAY 2, 2026



Lymphoma Committee

# Lymphoma Committee

## Leadership

Chair-Elect: ..... Sonali M. Smith, MD  
 Vice-Chair: ..... TBD  
 Executive Officer:..... Alex Herrera, MD  
 Statisticians: .....Michael LeBlanc, PhD  
 ..... Hongli Li, MS  
 ..... Gabby Lopez, MS  
 ..... Matt Chansky, BS

## Scientific Leadership

Translational Medicine:..... Alexey Danilov, MD, PhD  
 Radiation Oncology: ..... Nicholas Burden Figura, MD  
 Imaging:..... Lawrence H. Schwartz, MD  
 Immunotherapeutics: ..... Sweetha Thiruvengadam, MD  
 Pathology:..... Joo Y. Song, MD  
 Early Therapeutics: ..... Nasheed Mohammad Hossain, MD

## Designates

Adolescent & Young Adults: ..... Boyu Hu, MD  
 Cancer Control:..... TBD  
 Veterans Affairs: ..... Helen Ma, MD  
 Data Coordinators: ..... Alex Rangel, BS  
 ..... Gabi Herbert, MS, BS  
 ..... Laura Wells, BA  
 .....Daria Chugina, MD, CCRPS  
 Oncology Research Professionals: ..... Erin M. Cebula, MPH  
 ..... Jacob Kedroske, BA  
 Patient Advocate:..... Tricia Hernandez, MS  
 Pharmaceutical Science:.....Dawud Nael Dawud Ellayan, PharmD  
 .....Martina Fraga, PharmD  
 Protocol Project Manager:..... Erin Rogers  
 Clinical Trials Program Manager:..... Laura Gildner, MS

## Time/Location

Saturday, May 2, 2026 11:45 a.m. - 1:45 p.m.  
 Room: Grand Ballroom A (Street Level)

## Agenda

1. **Welcome & Introductions** - Sonali Smith, MD
2. **Looking Back and Looking Forward: SWOG Lymphoma Committee Efforts Over the Past Decade**
  - Follicular Lymphoma
  - Hodgkin Lymphoma
  - DLBCL
  - Correlative Sciences

## 3. New studies

S2506: Marginal zone lymphoma - Dr. Hu  
 S2504: Richter’s transformation - Dr. Shadman

## 4. SWOG Trial Updates

- |    |                             |   |
|----|-----------------------------|---|
| a. | S2308                       | Nilanjan Ghosh, MD, PhD                       |
| b. | S2207                       | Jennifer Amengual, MD /<br>Patrick Reagan, MD |
| c. | S1925 CLL                   | Deborah Stephens, DO                          |
| d. | S1918 phase 2 result timing | Elizabeth Brem, MD /<br>Sonali Smith, MD      |

## 5. Open Studies From Other Groups

- |    |                    |                       |
|----|--------------------|-----------------------|
| a. | EA4232 T-cell ASCT | Marc Hoffmann, MD     |
| b. | AO51902 T-cell     | Jennifer Amengual, MD |
| c. | AO52101 older MCL  | Tyrel Phillips, MD    |
| d. | AHOD2131 HL        | Boyu Hu, MD           |

## Developing Studies

**S2506**, “MOZART MZL: A Randomized 3-Arm Phase II Study Evaluating Mosunetuzumab Alone and In Combination with Either Zanubrutinib or Polatuzumab Vedotin for The Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma.” Drs. B. Hu, B. Hu, and S. Smith.

## Active Studies

**S1918**, “A Phase II/III Randomized Study of R-miniCHOP With or Without CC-486 (Oral Azacytidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.” Drs. E. Brem and S. Smith. Activated: 3/19/21. Temporarily closed to accrual: 4/1/25.

**S2114**, “A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma.” Drs. B. Hess and N. Hossain. Activated: 2/23/2023.

**S2207**, “Randomized phase II study of the addition of Targeted therapeutic agents to tafasitamab-based therapy in non-transplant-eligible patients with Relapsed/refractory Large B-cell Lymphoma.” Drs. J. Amengual, P. Reagan, and S. Smith. Activated: 6/30/2023

# Lymphoma Committee

**S2308**, “Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma.” Drs. N. Ghosh and J. Friedberg. Activated: 8/1/2024

**CTSU/A051902**, “A Randomized Phase II Study of CHO(E)P vs Oral Azacitidine-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas.” Dr. Mehta-Shah. SWOG Champion: Dr. J. Amengual. Activated 7/30/2021. Temporarily closed to accrual: 8/4/25.

**CTSU/A052101**, “A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON).” Dr. Beaven. SWOG Champion: Dr. T. Phillips. Activated 09/08/2023.

**CTSU/AHOS2131**, “A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma.” Dr. Henderson. SWOG Champion: Dr. B. Hu. Activated 04/28/2023.

## Closed Studies

**S1608**, “Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma.” Dr. P. Barr. Activated: 8/10/17. Closed: 7/15/2024

**CTSU/A051701**, “Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas.” Dr. Abramson. SWOG Champion: Dr. S. Smith. Activated: 8/7/19. Closed: 12/14/2023.

**CTSU/ANHL1931**, “A Randomized Phase 3 trial of Nivolumab in Combination with Chemo immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B cell Lymphoma.” Dr. Roth. SWOG Champion: Dr. M. Kamdar. Activated 6/7/2021. Closed: 5/28/25.

**CTSU/EA4151**, “A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission.” Dr. Fenske. SWOG Champion: Dr. B. Till. Activated: 8/29/17. Closed 10/3/24.

**CTSU/EA4181**, “A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CA-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients  $\leq$  70 years Old with Untreated Mantle Cell Lymphoma.” Dr.

Wagner-Johnson. SWOG Champion: Dr. S. Spurgeon. Activated: 10/3/19. Closed: 4/7/2023

## Active Leukemia Studies

**S1905**, “A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL).” Drs. Advani, N.Papadantonakis, and C. Yueng. Activated: 8/17/20.

**S1925**, “A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study.” Dr. D. Stephens. Activated: 12/14/20.

## Developing Leukemia Studies

**S2504**, “A Randomized Phase II Study of Pirtobrutinib Plus R-CHOP vs. R-CHOP for Patients with Previously Untreated Richter Transformation (RT).” Drs. M. Shadman, D. Stephens, and A. Danilov.

## Closed Cancer Care Delivery Study

**S1912CD**, “A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT).” Dr. V. Shankaran. Activated 7/26/2021. Closed 12/16/2024.

# Lymphoma Committee

## Publications

The publication papers listed below from 2025 and 2026 have not appeared in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

### Published/Accepted Manuscripts

**S0016** Development and Validation of a Gene Expression Signature to Predict Early Events in Patients with Follicular Lymphoma. C Ramsower, G Wright, H Li, J Cerhan, M Mauer, R Mwangi, A Rosenthal, A Novak, B Link, T Witzig, T Habermann, R Kridel, M LeBlanc, M Shadman, S Smith, J Friedberg, D Scott, C Steidl, L Staudt, L Rimsza. *Blood Advances* 2025 Dec 23;9(24):6443-6454. doi: 10.1182/bloodadvances.2025016827.  
<https://pubmed.ncbi.nlm.nih.gov/40966421/>

**S0016** Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial. Mazyar Shadman, Michael LeBlanc, Lisa Rimsza, John P Leonard, Sonali M Smith, Hongli Li, Jonathan W Friedberg. *JAMA Oncology*. 2026 Feb 26:e260042. doi: 10.1001/jamaoncol.2026.0042. Online ahead of print. PMC12947078.  
<https://pubmed.ncbi.nlm.nih.gov/41746629/>

**S0816/Other** Advanced Stage classical Hodgkin Lymphoma Patients with a Positive Interim-PET (PET-2) Deauville Score 5 After 2 ABVD Cycles: A Pooled Analysis of Three Multicenter Trials. S Viviani, S Pavoni, S Barrington, L Guerra, H Schoder, P Johnson, A Kirkwood, D Stephens, J Friedberg, S Chauvie, M Knopp, S Luminari, D Molin, P Corradini, A Gallamini, A Rambaldi, C Tarella. *Blood Cancer Journal*. 2025 Oct 16;15(1):165. doi: 10.1038/s41408-025-01364-z.  
<https://pubmed.ncbi.nlm.nih.gov/41102172/>

**S1826** Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. Reply. AF Herrera, M LeBlanc, JW Friedberg. *N Engl J Med*. 2025 Jan 2;392(1):102. doi: 10.1056/NEJMc2414269.  
<https://pubmed.ncbi.nlm.nih.gov/39752312/>

**S1826** Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826. Sharon M Castellino, Hongli Li, Alex F Herrera, Michael LeBlanc, Susan K Parsons, Joseph M Unger, Angela Punnett, David Hodgson, Frank G Keller, Richard A Drachtman, Adam Lamble, Christopher J Forlenza, Andrew Doan, Sarah C Rutherford, Andrew M Evens, Richard F Little, Malcolm A Smith, Bradford S Hoppe, Joo Y Song, Sonali M Smith, Jonathan W Friedberg, Kara M Kelly. *J Clin Oncology* 2026 Feb 20;44(6):449-454. doi: 10.1200/JCO-25-00203. Epub 2026 Jan 9.  
<https://pubmed.ncbi.nlm.nih.gov/41512237/>

## Submitted Manuscripts

**S1001/Others** Development and validation of a novel conditional event-free survival tool in diffuse large B-cell lymphoma. Z Chen, D Luan, R Rask, L Jakobsen, M Maurer, T El-Galaly, L Nastoupil, J Cerhan, C Flowers, B Link, I Lossos, D Stephens, J Cohen, J Habermann, G Nowakowski, N Bartlett, J Friedberg, B Kahl, J Leonard, P Brown, K Smedby, M Jerkeman, P Martin. Submitted 2025.

**S1826** Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826). Sairah Ahmed, Hongli Li, Alex F. Herrera, Anamarija M. Perry, Alexandra E. Kovach, Sarah C. Rutherford, Kelly Davison, Sharon M. Castellino, Andrew M. Evens, Brad Kahl, Nancy L. Bartlett, John P. Leonard, Margaret A. Shipp, Sonali M. Smith, Kara M. Kelly, Michael LeBlanc, Jonathan W. Friedberg, Joo Y. Song. Submitted 2026.

## Lymphoma Committee

**Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study**

	S1608	S1918	S2114	S2207	S2308	A051902	A052101	AHOD2131	ANHL1931
Banner University Medical Center - Tucson	2	-	2	-	3	-	-	-	-
Baptist Mem Health Care/Mid So Minority Underserved NCORP	-	1	2	-	1	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	4	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	3	-	5	-	-	-	-	5	-
Cancer Research for the Ozarks NCORP	1	1	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	2	-	3	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	14	-	13	-	-	-	-
Cedars-Sinai Medical Center	-	1	-	6	2	-	-	3	1
City of Hope Comprehensive Cancer Center	8	11	-	-	9	-	-	19	15
Columbia University Minority Underserved NCORP	-	6	6	2	-	3	-	1	3
Columbus NCI Community Oncology Research Program	1	-	-	-	-	-	-	-	-
Dartmouth College - Dartmouth Cancer Center LAPS	-	-	1	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-	-	2	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	1	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	7	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	5	-	6	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	2	-	-	1	-	-	-	-
Gulf South Minority Underserved NCORP	-	2	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	1	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	1	-	-	-	2	-	-	-	-
Henry Ford Hospital	-	-	-	-	2	-	-	3	-
Intermountain Medical Center	-	1	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	3	3	-	-	-	-	-	8	-
Loyola University Medical Center	-	-	2	-	-	-	-	-	-
Medical University of So Carolina Minority Underserved NCORP	2	3	21	-	5	-	-	2	-
Michigan Cancer Research Consortium NCORP	1	8	-	1	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	1	-	-	-	-	-	1
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-	-

## Lymphoma Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1608	S1918	S2114	S2207	S2308	A051902	A052101	AH02131	ANHL1931
Northwestern University LAPS	1	-	-	-	-	-	-	-	1
Ohio State University Comprehensive Cancer Center LAPS	-	2	-	-	4	-	-	-	-
Oregon Health and Science University	-	-	4	-	5	-	-	5	-
Pacific Cancer Research Consortium NCORP	-	-	12	1	2	-	-	-	-
Rhode Island Hospital	-	-	-	-	1	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	6	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	7	-	-	-	-	-	-	2
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-	-
U of Alabama at Birmingham / Deep So Research Consortium LAPS	-	-	-	-	7	-	-	-	-
University of Arkansas for Medical Sciences	-	-	9	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	1	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-	7	-	-	1	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	8	-	16	-	5	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-	-
University of Nebraska Medical Center	-	-	-	-	-	-	2	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	1	-	-	-	-	-	-
University of Rochester LAPS	16	-	10	8	16	8	16	25	10
University of Texas Health Science Center at San Antonio	-	-	-	2	-	-	-	1	-
University of Texas MD Anderson Cancer Center LAPS	3	-	-	-	19	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	1	12	-	-	7	-	-	8	-
Upstate Carolina Consortium Community Oncology Research Prog	1	1	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	5	-	1	-	1	-	-
Wisconsin NCI Community Oncology Research Program	-	2	-	-	2	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	1	1	-
ALLIANCE	17	42	55	7	54	-	-	-	-
ECOG-ACRIN	5	17	13	-	28	-	-	-	-
NRG	11	7	7	4	11	-	-	-	-
<b>Total</b>	<b>78</b>	<b>136</b>	<b>183</b>	<b>34</b>	<b>232</b>	<b>19</b>	<b>26</b>	<b>82</b>	<b>33</b>

## Lymphoma Committee

**Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study**

	EA412	EA4151	EA4232
Banner University Medical Center - Tucson	-	1	-
Baptist Mem Health Care/Mid So Minority Underserved NCORP	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	23	-
Cancer Research Consortium of West Michigan NCORP	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	14	-
Cedars-Sinai Medical Center	-	-	-
City of Hope Comprehensive Cancer Center	-	18	-
Columbia University Minority Underserved NCORP	1	-	-
Columbus NCI Community Oncology Research Program	-	-	-
Dartmouth College - Dartmouth Cancer Center LAPS	-	-	-
Duke University - Duke Cancer Institute LAPS	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	15	-
Froedtert and the Medical College of Wisconsin LAPS	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-
Gulf South Minority Underserved NCORP	-	-	-
Hawaii Minority Underserved NCORP	-	-	-
Heartland Cancer Research NCORP	-	-	-
Henry Ford Hospital	-	-	-
Intermountain Medical Center	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	11	-	-
Loyola University Medical Center	-	5	-
Medical University of So Carolina Minority Underserved NCORP	-	2	-
Michigan Cancer Research Consortium NCORP	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	2	-
Nevada Cancer Research Foundation NCORP	1	-	-

## Lymphoma Committee

**Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study**

	E4412	EA4151	EA4232
Northwestern University LAPS	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-
Oregon Health and Science University	-	7	-
Pacific Cancer Research Consortium NCORP	-	-	-
Rhode Island Hospital	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-
UC San Diego Moores Cancer Center	-	1	-
U of Alabama at Birmingham / Deep So Research Consortium LAPS	7	5	-
University of Arkansas for Medical Sciences	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	2	-
University of Colorado Cancer Center LAPS	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-
University of Kentucky/Markey Cancer Center	-	3	-
University of Nebraska Medical Center	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-
University of Rochester LAPS	-	11	1
University of Texas Health Science Center at San Antonio	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	20	-
Upstate Carolina Consortium Community Oncology Research Prog	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	1	-
Wisconsin NCI Community Oncology Research Program	-	-	-
Yale University - Yale Cancer Center LAPS	-	5	-
ALLIANCE	-	-	-
ECOG-ACRIN	-	-	-
NRG	-	-	-
<b>Total</b>	<b>20</b>	<b>135</b>	<b>1</b>

